Patient spending on prescription drugs fell in 2012 -- for the first time ever, a new study reports -- due in part to expiring patents on brand-name drugs.
[More]
Consumer Reports offers new analysis that finds not all patients realize they can save big by shopping around for drugs. Meanwhile, two outlets look at insurance coverage issues for couples.
[More]
Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.
[More]
A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.
[More]
The disease atherosclerosis involves the build up of fatty tissue within arterial walls, creating unstable structures known as plaques. These plaques grow until they burst, rupturing the wall and causing the formation of a blood clot within the artery. These clots also grow until they block blood flow; in the case of the coronary artery, this can cause a heart attack.
[More]
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
[More]
Scripps Health announced today that it has been awarded a $3.75 million grant from the Qualcomm Foundation, to be used for the Scripps Translational Science Institute, which was established by Scripps Health in collaboration with various parties to support the development of breakthrough digital technologies designed to revolutionize the practice of medicine.
[More]
Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.
[More]
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).
[More]
If brand-name prescription medicines cost you as little as generic pills, which would you choose? A few drugmakers are betting Americans will stick with the name they know. They've begun offering U.S. patients coupons to reduce copayments on brand-name medicines and compete with new generic versions of the drugs.
[More]
Today's headlines include reports from the campaign trail, where House candidates are turning up the Medicare debate; and from the health care marketkplace, where Aetna acquired Coventry Health, a Medicare and Medicaid insurer.
[More]
The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.
[More]
Vibrational circular dichroism (VCD), a new tool for determining the absolute configuration of chiral molecules, was a key highlight of the recent 24th International Symposium on Chirality, held June 10-13 in Fort Worth, Texas. VCD pioneer, BioTools (Jupiter, FL) was on hand, not only sponsoring the exhibitor’s luncheon and the poster awards, but also proudly awarding the Best Poster Given by a Young Scientist for the thirteenth year.
[More]
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
[More]
HealthWarehouse.com, Inc. a leading VIPPS accredited retail mail-order pharmacy, today announced its financial results for the year ended December 31, 2011.
[More]
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
[More]
One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.
[More]
Patients taking the popular blood thinner Plavix now have the option of getting a less-expensive pill, following the approval Thursday of the first generic versions in the U.S. That's because the patent for Plavix, the world's second-best-selling medicine, just expired. Plavix is taken by millions of people every day to prevent heart attacks and strokes, by preventing platelets in the blood from clumping together.
[More]
Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.
[More]
Dr. Reddy's Laboratories announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX, in the U.S. market on May 18, 2012.
[More]